Latest news with #bioprocessing
Globe and Mail
27-05-2025
- Business
- Globe and Mail
Scientific Industries to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025
BOHEMIA, N.Y., May 27, 2025 (GLOBE NEWSWIRE) -- Scientific Industries, Inc. (OTCQB: SCND), a life sciences tool provider, and a developer of digitally simplified bioprocessing products, announced it will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2025 Investor Conference, taking place virtually on Thursday, May 29, 2025. Company Webcast The webcast presentation will take place at 12:30 p.m. ET on Thursday, May 29, 2025. The webcast can be accessed by visiting the conference home page at or directly at The webcast will also be available for replay following the event. 1x1 Meetings Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1x1@ or register for the event at About Scientific Industries, Inc. Scientific Industries (OTCQB: SCND), is a life science tool provider. It designs, manufactures, and markets laboratory equipment, including the world-renowned Vortex-Genie ® 2 Mixer and Torbal ® balances, and bioprocessing systems under the product name DOTS. Scientific Industries' products are generally used and designed for research purposes in laboratories of universities, hospitals, pharmaceutical companies, medical device manufacturers, and pharmacies. To learn more, visit About Scientific Bioprocessing, Inc. Scientific Bioprocessing, Inc. (SBI) is dedicated to pioneering digitally simplified bioprocessing by providing actionable insights from lab to production floor. With a broad portfolio of state-of-the-art bioprocess sensors and actuators as well as innovative data analytics software, SBI helps scientists and engineers in bioprocessing to monitor and control critical process parameters and product quality attributes. SBI is a subsidiary of Scientific Industries Inc. (SCND-OTCQB) To learn more, visit Safe Harbor Statement Statements made in this press release that relate to future events, performance or financial results of the Company are forward-looking statements which involve uncertainties that could cause actual events, performance or results to materially differ. The Company undertakes no obligation to update any of these statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as to the date hereof. Accordingly, any forward-looking statement should be read in conjunction with the additional information about risks and uncertainties set forth in the Company's Securities and Exchange Commission reports, including our annual report on Form 10-K.
Globe and Mail
22-05-2025
- Business
- Globe and Mail
Repligen Corporation to Present at William Blair Growth Conference
WALTHAM, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating at the William Blair 45 th Annual Growth Stock Conference being held June 3 – 5 in Chicago. Olivier Loeillot, President and Chief Executive Officer is scheduled to present a company overview on June 3 rd at 1:20 p.m. CT. A live webcast of the conference presentation will be accessible through Repligen's Investor Relations website at and will be available for replay for a limited period of time following the event. About Repligen Corporation Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are 'inspiring advances in bioprocessing' for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the company see our website at and follow us on LinkedIn.
National Post
14-05-2025
- Business
- National Post
Ecolab Life Sciences Opens New State-of-the-Art Bioprocessing Applications Laboratory in Pennsylvania, US
Article content ST. PAUL, Minn. — Ecolab Life Sciences has officially opened its new US Bioprocessing Applications Laboratory in King of Prussia, Pennsylvania. Article content Article content The new facility is designed to support biopharma customers with applications and process development for the purification of biotherapeutic molecules, providing comprehensive technical support to biopharmaceutical companies and contract manufacturers operating from small-scale to full commercial production. This new development location is well positioned in the Eastern U.S., close to many large pharmaceutical operations and a hub of bioprocessing innovation. Article content The lab is equipped with high-throughput process development tools and manufacturing scale chromatography columns, enabling biotech firms to receive turnkey support for process development. Large biopharma companies can utilize the applications lab throughout the entire development cycle, from early to late stage and commercialization; including characterizing alternative resins to help reduce manufacturing costs and support with regulatory submissions. Article content 'Our new Bioprocessing Applications Lab marks a significant milestone in our ability to be a global technical partner to our customers around the world,' said Jennifer Sorrells, Ph.D., vice president of research and development, Ecolab Life Sciences. 'This facility demonstrates our commitment to delivering best-in-class bioprocessing solutions by pairing Ecolab's innovative resin toolbox with deep domain expertise to optimize the purification process. We are dedicated to empowering our customers to accelerate the delivery of life-saving therapies to market.' Article content Biopharma and contract manufacturing organizations are already leveraging Ecolab's Bioprocessing Applications Lab to help accelerate speed and enhance manufacturing efficiencies through lifecycle studies. The lab can initiate studies and deliver results within weeks, facilitating a faster route to market while providing customers with access to raw data and bench-level operations for transparency and collaboration. Article content The new lab complements Ecolab's existing European Applications and Research & Development Lab, in Wales, U.K., and is part of the Ecolab Life Sciences Pharma Center of Excellence, a multi-million dollar investment which also includes an interactive learning space, The Xchange customer experience center, and an API (Active Pharmaceutical Ingredient) and excipient manufacturing facility. Article content A trusted partner for millions of customers, Ecolab (NYSE:ECL) is a global sustainability leader offering water, hygiene and infection prevention solutions and services that protect people and the resources vital to life. Building on more than a century of innovation, Ecolab has annual sales of $16 billion, employs approximately 48,000 associates and operates in more than 170 countries around the world. The company delivers comprehensive science-based solutions, data-driven insights and world-class service to advance food safety, maintain clean and safe environments, and optimize water and energy use. Ecolab's innovative solutions improve operational efficiencies and sustainability for customers in the food, healthcare, high tech, life sciences, hospitality and industrial markets. Article content Article content Article content Article content Article content Contacts Article content Article content Article content
